Best Oncology Companies in Beijing, China
The 43 best Oncology companies in Beijing, China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Avistone.
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Beijing
| # | Company | Disclosed funding | Last round | Stage | Founded | Founder | Employees | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Avistone Developer of precision therapeutics for oncology 32Funding top 26%Moat top 38%Talent bottom 49%Market bottom 37% All 5 signals ▾Fundingtop 26% Moattop 38% Talentbottom 49% Marketbottom 37% Globalbottom 36% Funding: Raised $340M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 32/100 | $340M | 32 mo ago | Series B | 2012 | Shi Hepeng Founder & CEO | — | — | — |
| 2 | InnoCare Developer of small molecule based therapeutics for the treatment of cancer and autoimmune disorders | $215M | 91 mo ago | Public | 2015 | Jasmine Cui Co-Founder & CEO | 1,072 | — | 1 award |
| 3 | Beijing Mabworks Biotech Developer of anticancer therapies | $214M | 76 mo ago | Series C | 2003 | — | 285 | — | — |
| 4 | Canbridge Life Sciences Developer of therapeutics for rare diseases and cancer | $186M | 62 mo ago | Public | 2012 | — | 17 | — | — |
| 5 | Zhejiang Nuhui Health Technology Provider of early cancer screening and testing services | $152M | 73 mo ago | Public | 2013 | Yiyou Chen Co-Founder | 1,041 | — | — |
| 6 | Xiantong Pharmaceutical Developer of radiopharmaceuticals for the diagnosis of tumors, neurodegenerative diseases and cardiovascular… | $100M | 37 mo ago | Series E | 2004 | — | 400 | — | — |
| 7 | Pyrotech Manufacturer of therapeutics for inflammatory and oncology conditions | $97M | 27 mo ago | Series A | 2020 | TJ Deng Co-Founder & CEO | 10 | 2 patents Innovative star‑shaped glass curtain‑wall façade systems for building envelopes. | — |
| 8 | Heyuan Biotechnology Developer of immune cell therapy drugs | $79M | 58 mo ago | Series C | 2018 | Lu Wei CEO | — | — | — |
| 9 | Luzhu Biotech Developer of human vaccines and biological drugs for multiple diseases | $73M | 50 mo ago | Public | 2001 | Jian Kong CEO | 129 | — | — |
| 10 | Beijing Jiakesi drug development Developer of small molecule based therapeutics for cancer treatment | $55M | 95 mo ago | Public | 2015 | — | 300 | — | — |
| 11 | TCRCure Biopharma Developer of cell therapies to treat cancer | $47M | 54 mo ago | Series B | 2016 | — | 70 | 51 patents Engineered immune cell therapies: synthetic cytokine signaling, CAR‑T receptors, anti‑PD‑1 antibodies. | — |
| 12 | Boomray Developer of radionuclide-targeted drugs for diagnosis and treatment of cancer | $43M | 47 mo ago | Series A | 2021 | Hu Jiangbin CEO | — | 3 patents Inhibitors targeting fibroblast activation protein for therapeutic applications | — |
| 13 | Huaxia Yingtai Biotechnology Developer of CAR-T cell therapies for treating cancer | $38M | 58 mo ago | Series B | 2018 | Lin Xin Founder | — | — | — |
| 14 | Beijing Zhidao Biotechnology Developer of cytokines for treating cancer | $29M | 43 mo ago | Series C | 2014 | Zhang Wei CEO | — | — | — |
| 15 | Beijing Zhongyin Technology Digital clinical genetic diagnosis tool for providers 42Funding top 41%Talent bottom 45%Global bottom 29% All 3 signals ▾Fundingtop 41% Talentbottom 45% Globalbottom 29% Funding: Raised $26.5M · 3 rounds over 5 yrs (0.6/yr) Talent: 1 named leader on record rank vs industry peers · Fliar Intelligence Index 42/100 | $26M | 34 mo ago | Series A | 2015 | Zhong Xiancheng CEO | — | — | — |
| 16 | Sheng Nuoji Medicine Provider of tumor and immunoinflammatory drugs | $20M | 156 mo ago | Series C | 2006 | — | 186 | — | — |
| 17 | Beijing Youxun Medical Laboratory Provider of tests for detecting non-invasive single gene disorders, prenatal testing and tumor detection | $15M | 51 mo ago | Series B | 2014 | Ye Zhou CEO | — | — | — |
| 18 | Youhe Medical Technology Developer of antibodies for cancer | $10M | 110 mo ago | Series A | 2016 | Shen Yuelei Co-Founder | — | — | — |
| 19 | Novi Biotech Developer of gene therapies for cancer treatment | $7M | 34 mo ago | Series A | — | Liu Defang CEO | — | — | — |
Top 12 Oncology companies in Beijing
#1
Series B · Beijing, Beijing · founded 2012$340Mraised▾
Developer of precision therapeutics for oncology. It offers a lead compound PLB1004, a novel mono-anilino-pyrimidine small molecule inhibitor of EGFRa that has anti-tumour effect.
- Dec 2023Series B$140M
- Dec 2021Series A$200M
#2
Series A · Beijing, Beijing · founded 2020 · 10 employees$96.9Mraised▾
Manufacturer of therapeutics for inflammatory and oncology conditions. The company develops small molecule and biologic immunomodulators to advance clinical studies and the pipeline for inflammation-related diseases as diverse as cancer, sepsis and Alzheimer’s.
- May 2024Series A—
- Jul 2023Series A$96.9M
#3
Series E · Beijing, Beijing · founded 2004 · 400 employees$99.5Mraised▾
Developer of radiopharmaceuticals for the diagnosis of tumors, neurodegenerative diseases, and cardiovascular diseases. The company has developed nuclear medicine for the treatment. It has also developed several diagnostic agents.
- Jul 2023Series E—
- Oct 2021Series D$50M
- Feb 2021Series D$49.5M
#4
Series A · Haidian, Beijing · founded 2015$26.5Mraised▾
Developer of clinical genetic diagnosis, fertility prevention and gene therapy drug for hereditary eye diseases. The company specializes in developing ophthalmic gene therapy drugs backed by accurate gene diagnosis, providing reliable ophthalmic gene pharmaceuticals for the public.
#5
Public · Beijing, Beijing · founded 2012 · 17 employees$186Mraised▾
Developer of therapeutics for rare diseases and cancer. Its drug pipeline includes CAN-008, an antibody that blocks the CD95 ligand & from binding to CD95 for glioblastoma, CAN-002, a supersaturated calcium phosphate oral rinse solution indicated for mucositis caused by radiation or high dose chemotherapy, CAN-017 an antibody for first in squamous cell esophageal cancer.
- Jun 2021Series E—
- Dec 2020Series E$43M
- Feb 2020Series D$98M
- May 2017Series B$25M
#6
Public · Tongzhou, Beijing · founded 2001 · 129 employees$72.9Mraised▾
Developer of human vaccines and biological drugs for multiple diseases. The company's product K193 is a bispecific antibody targeting human CD19 and CD3ε for the treatment of B-cell lymphoma and leukemia. Also, offer recombinant herpes zoster vaccine, Anti-human tumor necrosis factor-a monoclonal antibody injection, and others.
- Jun 2022Series C—
- Jan 2022Series B$18.9M
- Aug 2021Series B$54.1M
#7
Public · Beijing, Beijing · founded 2013 · 1041 employees$151.8Mraised▾
Provider of early cancer screening and testing services. The company has developed a fecal gene analysis (FIT-DNA) technology for colorectal cancer screening. The company also has a product for gastric cancer detection through their Helicobacter pylori toxicity factor detection technology. The company leverages its expertise in genetic testing, molecular diagnostics, and large data platforms and software in developing early detection tests for cancer.
- Jul 2020Series E$30M
- Apr 2020Series D$20M
- May 2019Series C$66M
- Aug 2017Series B$20M
#8
Series C · Beijing, Beijing · founded 2014$29.3Mraised▾
Leto develops cytokines for treating cancer. It produces Leukaemia Inhibitory Factor (LIF) is a multifunctional growth factor. It has a range of effects on cell growth, proliferation, and differentiation. Embryonic Stem Cells (ESC) are derived from the inner cell mass of cells that develop into the blastocyst stage after in vitro fertilization. They can be cultured in vitro for the renewal and having telomerase activity.
- Dec 2022Series C$14.4M
- Oct 2020Series B$14.8M
#9
Series A · Beijing, Beijing$6.8Mraised▾
Developer of gene therapies for cancer treatment
#10
Series C · Beijing, Beijing · founded 2003 · 285 employees$214.4Mraised▾
Beijing Mabworks Biotech is developing anticancer therapies. The lead candidate of the company MIL 60, it inhibits the activity Vascular endothelial growth factor (VEGF), a tyrosine kinase receptor inhibitor. The candidate is in phase III clinical studies. They have developed a dual function antibody technology platform.
- Apr 2020Series C$160M
- 2017Series B—
- Jan 2017Series B$39.3M
- May 2016Series A$15.2M
#11
Series A · Changping District, Beijing · founded 2021$43Mraised▾
Developer of radionuclide-targeted drugs for diagnosis and treatment of cancer. The company's pipeline includes multiple FIC/BIC nuclide conjugated drugs and neutron capture therapy drugs, involving multiple different indications including head and neck tumors, brain tumors, pancreatic cancer, inflammatory cancer identification, and other diagnostic applications.
- Sep 2022Series A$43M
#12
Series C · Chaoyang, Beijing · founded 2018$78.7Mraised▾
Juventas is a developer of immune cell therapy drugs for the treatment of blood cancers. The drugs developed are HY001 (acute lymphoblastic leukemia), HY002 (acute myeloid leukemia) and HY015 (multiple myeloma).
- Oct 2021Series C$64.2M
- Jul 2019Series A$14.5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Oncology in Beijing is moving
A read on the academic research around Oncology in Beijing — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 822 papers.
- Beijing University of Chinese Medicine73
- Beijing University of Chemical Technology71
- Beijing Tian Tan Hospital57
- Beijing Friendship Hospital57
- Beijing National Laboratory for Molecular Sciences48
- In vivo1→21
- Biophysics1→4
- Tumor microenvironment1→199
- Immune system1→176
- Cancer research1→112
- Lung cancer1→20
- PD-L11→3
- Immunotherapy32
- Immune system29
- Tumor microenvironment26
- Cancer immunotherapy12
- Cancer11
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.